Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics crawled time : 13:02 save search
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2020 Financial Results
Published: 2021-02-19 (Crawled : 13:02) - globenewswire.com
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: 1.48%
H: 14.02%
C: 6.34%
financial results results
F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1
Published: 2021-01-20 (Crawled : 13:02) - globenewswire.com
FSTX | $7.12 0.0% 0
|
Health Technology
|
| O: 4.16%
H: 8.73%
C: 3.58%
antibody patent granted grant
Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network
Published: 2020-12-18 (Crawled : 13:02) - globenewswire.com
ATXI | $0.0949 -29.18% -41.2% 12M
|
Health Technology
|
| O: -9.91%
H: 48.47%
C: 28.11%
CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV
Published: 2020-12-14 (Crawled : 13:02) - globenewswire.com
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: 3.44%
H: 4.2%
C: -2.25%
crispr therapy hiv granted grant
Aditxt Signs Distribution Agreement with Todos Medical Ltd. For AditxtScore™ for COVID-19 Immune Monitoring Service
Published: 2020-12-14 (Crawled : 13:02) - globenewswire.com
ADTX | $2.27 2.84% 27K
|
Health Technology
|
| O: 2.02%
H: 2.37%
C: -12.25%
covid distribution covid-19
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis
Published: 2020-12-10 (Crawled : 13:02) - globenewswire.com
TGTX | $13.99 -1.83% -1.86% 2.7M
|
Health Technology
|
| O: 11.75%
H: 29.43%
C: 26.04%
positive therapy multiple sclerosis results sclerosis phase 3 treatment topline
Aditxt to Present at the 13th Annual LD Micro Main Event Conference
Published: 2020-12-08 (Crawled : 13:02) - globenewswire.com
ADTX | $2.27 2.84% 27K
|
Health Technology
|
| O: 0.51%
H: 3.05%
C: 0.0%
Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy
Published: 2020-12-07 (Crawled : 13:02) - globenewswire.com
ENLV | News | $1.52 15.15% 13.16% 130K
|
Health Technology
|
| O: -4.59%
H: 1.3%
C: -7.04%
chinese therapy immunotherapy patent
Aligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Oligonucleotide Therapy for NASH
Published: 2020-12-07 (Crawled : 13:02) - globenewswire.com
ALGS | $0.8204 -0.39% -0.39% 640K
|
Health Technology
|
| O: 0.35%
H: 13.11%
C: 8.99%
license collaboration therapy research nash
Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting
Published: 2020-12-07 (Crawled : 13:02) - globenewswire.com
ONCT | $8.755 -0.11% -0.11% 1.6K
|
Health Technology
|
| O: 48.5%
H: 23.29%
C: 0.76%
phase 3 phase 1 phase 2
Nabriva Therapeutics Announces Date of 1-for-10 Reverse Stock Split
Published: 2020-12-02 (Crawled : 13:02) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: -15.91%
H: 11.16%
C: 6.43%
TG Therapeutics Announces Publication of Phase 2 Data Evaluating Umbralisib in Patients with Chronic Lymphocytic Leukemia Who Are Intolerant to Prior BTK or PI3K Inhibitor Therapy in Blood
Published: 2020-12-02 (Crawled : 13:02) - globenewswire.com
TGTX | $13.99 -1.83% -1.86% 2.7M
|
Health Technology
|
| O: 1.1%
H: 0.28%
C: -4.54%
therapy blood leukemia phase 2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.